Shamburg News · 8-K filed Nov 12, 2026, 8:41 AM EST
MetaVia Reports Additional Positive Phase 1 Part 3B Data for DA-1726, Including Uric Acid Reduction
MTVA · MetaVia Inc.
- Reg FD disclosure
- Other event
- Materiality: medium
On November 12, 2026, MetaVia Inc. announced additional positive data from the interim analysis of Part 3B of its Phase 1 trial of DA-1726, a GLP-1 and glucagon receptor dual agonist. The company reported a statistically significant 1.47 mg/dL placebo-adjusted reduction in serum uric acid at 16 weeks, with mean uric acid down 1.02 mg/dL from a 5.89 mg/dL baseline at Day 109. The press release was furnished as Exhibit 99.1 under Regulation FD, and the company plans full Part 3A and 3B data in Q1 2027 and a Phase 2 study in the second half of 2027.
Source: SEC EDGAR, Form 8-K, Items 7.01, 9.01, accession 0001104659-26-125964.
Written from the filing by Shamburg Markets. Figures are as reported by the company.